INTRODUCTION
Agammaglobulinemia is a heterogeneous immunodeficiency disease resulting from the failure of development or differentiation of bone marrow-derived (B) lymphocytes.' Most, but not all, patients with the X-linked form of agammaglobulinemia lack small B lymphocytes, as defined by surface Ig, C3 receptors, and Epstein-Barr virus (EBV) receptors (1) (2) (3) . Some
Received for publication 31 October 1977 and in revised form 5 (4, 5) . In contrast, patients diagnosed to have the common variable form of agammaglobulinemia usually have normal numbers of small B lymphocytes (6) (7) (8) (9) (10) . Their B cells fail to produce imunoglobulin in response to mitogenic stimulation. Lymphocytes from a few patients have been reported to respond to mitogenic stimulation by the production of intracellular immunoglobulin that was not secreted (6, 8, 10) .
In vitro stimulation of peripheral lymphocytes by mitogens, including pokeweed mitogen (PWM), lymphocyte mitogenic factor (LMF), or EBV, results in the increased synthesis and eventual secretion of IgM or IgG by B lymphocytes (11) (12) (13) (14) (15) . Morphologically, the small B lymphocytes enlarge and undergo mitosis, and differentiate into immunoglobulin-secreting lymphoblasts. In cultures stimulated by PWM and LMF, some of these lymphoblasts mature into plasma cells (15) . In cultures stimulated by EBV, some of the lymphoblasts are immortalized, giving rise to long-term lymphoid cell lines that secrete immunoglobulin, usually of several classes (16) (17) (18) . These cells have surface receptors for C3, Fc, and EBV and bear surface immunoglobulin, usually of several heavy chain classes.
We attempted to establish long-term lymphoid cell lines from agammaglobulinemic patients by in vitro transformation of lymphocytes with EBV. The ability of lymphocytes from patients with agammaglobulinemia to give rise to established cell lines would serve to characterize B-cell developmental stages present in the peripheral blood. Characterization of the immunologic properties of the cell lines would permit determination of B cell-associated defects including failure of immunoglobulin production. Finally, cell lines derived from agammaglobulinemic patients that failed to produce immunoglobulin might serve to define stages in B-cell development and differentiation. METHODS Patients. Lymphocytes from 14 patients with a primary diagnosis of agammaglobulinemia were used in experiments to start lymphoid cell lines (Table I) . Four patients were diagnosed to have the X-linked form of agammaglobulinemia. Before treatment, they had serum IgG < 50 mg/100 ml; IgM and IgA were undetectable. Onset of the disease in these patients was before 2 yr of age. Each patient had a maternal male relative with agammaglobulinemia. 10 patients were diagnosed to have the common variable form of agammaglobulinemia. Before treatment, IgG was < 200 mg/100 ml, IgM < 50 mg/100 ml, and IgA < 50 mg/100 ml. Onset of the disease ranged from before 2 yr of age to 50 yr of age. Two patients were brothers.
Lymphocytes from most of these 13 patients had been previously characterized by EAC3 rosette formation and surface immunofluorescence (3, 8) . Additionally, lymphocytes were fractionated on discontinuous gradients ofbovine serum albumin (BSA), yielding "precursor" cell, T cell-, and B cellrich fractions. B-lymphocyte fractions from patients with B cells had been tested for synthesis and secretion of Ig in vitro in response to a T cell-derived mitogen (LMF).
All patients except patient 1.14 were without other disease at the time of study. Patient 1.14 had a benign lymphoproliferative disorder. Peripheral blood was the source oflymphocytes from all patients except patient 1.14 from whom spleen cells were obtained at splenectomy. All patients were on gamma globulin replacement therapy. All Mo.), and lymphocytes were separated by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, N. J.) sedimentation (19) . Primary cultures were seeded at d 2 x 106 cells/ml in 10-ml cultures and were fed twice a week by allowing the cells to sediment at unit gravity for 1 h at 370C followed by removal of 3 ml of the supernate and replacement with 3 ml of fresh media. Primary cultures were initiated and maintained in medium composed of 100 ml RPMI 1629 (20), 20 ml fetal bovine serum (FBS), 1 ml horse serum, 1 ml of 100 mM sodium pyruvate, 1 ml of 100 x Eagle's "nonessential" amino acids (21) , 1 ml of mM 2-mercaptoethanol (22) and 1 (22) supplemented with 10% FBS, 1 ml of 1 x 104 U/ml sodium penicillin G, 1 X 104 ,ug/ml streptomycin sulfate, and 0.2 M L-glutamine, 1 ml Eagle's nonessential amino acids, and 1 ml of 1 mM sodium pyruvate/100 ml medium.
Three long-term lymphoid cell lines were used for normal controls. CCRF CEM is a T-cell line derived from a patient with acute lymphoblastic leukemia (26, 27) . LAZ 67 and RPMI 1788 are B-cell lines derived from normal donors.
Mononuclear peripheral blood lymphocytes were isolated from heparinized blood by density centrifugation over FicollHypaque gradients (19) . In some experiments, cells were fractionated into "precursor," T cell-, and B cell-rich fractions on discontinuous gradients of BSA (28) . The gradients were constructed in 2% decrements, starting with 35% as the bottom layer, and decreasing to 17% albumin (layer 1). Layers 1, 2, and 3 were pooled to form the precursor-cell fraction (17) , layers 4 and 5 were pooled to constitute the T cell-rich fraction 2, and layers 6, 7, and 8 were pooled to form the B cell-rich fraction 3. Monocyte contamination was almost completely confined to fraction 1. Rosette formation. For rosette formation, cells were suspended at 2 x 106 cells/ml in Earle's balanced salt solution (EBSS) with 2% FBS which had been absorbed with sheep erythrocytes (E). For E rosettes, 0.05 ml of a 10% suspension of E was added to 1 ml of cell suspension, incubated at 37°C for 30 min, centrifuged at 200 g for 5 min, and then incubated at 40C for 2 h. E coated with antibody and the first four components of complement (EAC3b) were prepared. EAC3d (mouse) was prepared with the substitution of fresh mouse serum for the human complement components. The purity of EAC3d reagent was verified by its failure to form rosettes with human erythrocytes, demonstrating the absence of EAC3b (29) (30) (31) .
One-tenth ml of 1% EAC3 was added to 0. Immunoglobulin synthesis and secretion. Cells were washed twice with EBSS and resuspended at 5 x 106 cells/ml in Eagle's minimal essential medium without leucine supplemented with 10% dialyzed FBS, 1 ml of 200 mM L-glutamine/100 ml medium, and 2 ,uCi [14C]leucine/ml (New England Nuclear, Boston, Mass.). The cells were incubated for 12-14 h, after which the supernatant medium was collected, the cells washed twice with EBSS, and lysed by the addition of Nonidet P-40 (Bethesda Research Laboratories, Rockville, Md.) to 0.6%. After 30 min, the cell lysate was centrifuged at 2,000 g for 20 min to remove cell debris.
Aliquots of the cell supernatant medium and the cell lysate were examined for Ig by the addition of specific antiserum, followed 1 h later by the addition of goat antiserum to rabbit IgG at equivalence. Controls included precipitation with normal rabbit serum and specific precipitation of solutions in which normal rabbit serum had been precipitated. The mixtures were incubated at 4°C overnight, washed three times with cold EBSS, and resuspended in 2% sodium dodecyl sulfate (SDS), 1% 2-mercaptoethanol. The reduced proteins were alkylated with iodoacetic acid.
Immune precipitates were electrophoresed in 7.5% acrylamide slab gels with SDS-phosphate buffer (36 (Table IV) . The third patient had a decreased number of EBV receptor-positive cells in relation to the number of surface Ig and EAC3b-and EAC3d-positive cells.
To ensure that the cells that expressed one B cellassociated property were the same cells that expressed other properties, we separated lymphocytes into "precursor," T cell-, and B cell-rich fractions on discontinuous BSA gradients. Normal lymphocytes in each of the three fractions coexpressed the four B cell-associated properties (Table V) . The precursor-cell fraction contained 21-24% EAC3b, EAC3d rosette-forming, surface Ig-bearing, and EBV receptor-positive cells; the T-cell fraction 2 contained about 5-7% such B-cell marked cells; and the B cell-rich fraction 3 contained 62-88% positive cells.
Peripheral lymphocytes from two patients were fractionated before examination (Table V) . Of primary concern is the B cell-rich fraction 3. From two patients, most of the cells in this fraction were EAC3b and EAC3d rosette forming and surface Ig bearing, but none ofthe cells was EBV receptor positive. The T cellrich and precursor-cell fractions from these two patients were also without EBV receptor-positive cells. Characterization of LCL. The six LCL derived from five agammaglobulinemic patients were examined for immunological characteristics associated with long-term B-lymphoid cell lines. These properties were C3 receptors, surface immunoglobulin, cytoplasmic immunoglobulin, and immunoglobulin synthesis and secretion. All LCL were studied during the 1st mo after being established. Because of the possiblity of restriction of immunoglobulin production with increasing time in culture, the cell lines were examined at least once more after 6-12 mo in culture. No drift of immune properties has been noted, even in cell lines that have now been in culture for more than 2 yr.
Cells from all six of the cell lines formed EAC3 rosettes in percentages varying between 37 and 66% (Table VI) . These values are comparable to the percent rosette-forming cells from B-LCL derived from normal individuals (30-70%). None of the LCL formed rosettes with E, indicating the B-cell character of these EBV-derived LCL.
Two cell lines (LAZ 135 and LAZ 165) showed surface fluorescence with antisera to y-, a-, ,u-, and 8-heavy chains (Table VI) cence only with antisera to 8-chains (Table VII) . The ,u-chains present on the surface of some of these cells were apparently not synthesized in sufficient quantity to cause intracellular fluorescence. 88% of the cells from LAZ 153 were fluorescent with antisera to 8-heavy chains and an additional 23% reacted with antiserum to ,-chains. The other cell line from this patient, S-2, showed low numbers of cells fluorescent with antisera to 8-, ,-, and a few (6%) to y-chains. Cells from LAZ 184 were similarly reactive with fluorescent antisera to 8-and ,u-heavy chains, and again a few cells (4%) to y-heavy chains. Supernatant medium and cytoplasmic lysate preparations from cells incubated with [14C]leucine were precipitated with antisera specific for ,u-, y-, a-, or 8-heavy chains, K-and X-light chains, human Ig (specific for y-, a-, u-, and 8-heavy chains and K-and X-light chains), or with normal rabbit serum. Each of these precipitates was redissolved, reduced, and alkylated, and electrophoresed in SDS-acrylamide gels. Fig. 1 shows the autoradiographs of electrophoretic gels containing precipitates obtained with antiserum to human Ig. Two of the LCL (LAZ 135 and LAZ 165) showed de novo Ig synthesis and secretion. IgG and IgM production were identified by mobility in the SDS-gels and by precipitation with antiserum to ,uand y-heavy chains. These two cell lines had surface IgG, A, M, and D. The remaining four cell lines (LAZ 153, LAZ 184, LAZ 202, and S-2) did not show de novo Ig production. LAZ 153 showed trace bands comigrating with y-and L chains; however, precipitation of radioactive material from 100 x 106 cells with antiserum to y-heavy chains failed to confirm the production of IgG by this cell line. These four cell lines produced a protein that comigrated with ,u-heavy chains. This protein was precipitable with antisera to y-, a-, and 8-heavy chains and with normal rabbit serum. The nonspecific precipitation and the absence of associated light chains indicate that this material was not immunoglobulin.
The determination of immunoglobulin production or lack of production was confirmed by a radioimmunoassay. By indirect precipitation, the percentage of TCA-precipitable protein that could be identified as immunoglobulin was determined. Immunoglobulin production was found in the cell lines LAZ 135 and LAZ 165. In contrast, the remaining four cell lines, LAZ 153, LAZ 184, LAZ 202, and S-2, failed to produce immunoglobulin detectable by this technique (Table VIII) (42, 43) . Cell lines derived from two patients, LAZ 135 and LAZ 165, had immune characteristics that were indistinguishable from LCL derived from normal individuals. These findings are in contrast to previous studies which showed that isolated B lymphocytes from patient 4.5 (LAZ 135) failed to respond to mitogenic stimulation (8) . Two explanations of this discrepancy suggest themselves. First, this patient may have normal, responsive B lymphocytes present in insufficient numbers to have been detected in previous studies. Alternatively, these B lymphocytes may be defective in mitogenic or antigenic triggering. EBV transformation may be able to circumvent such an intrinsic defect. If the latter explanation is correct, LAZ 135 and LAZ 165 may be defective in immunologic properties which were not tested in these studies.
Prolonged cultivation of a LCL may result in phenotypic restriction to production of a single class of immunoglobulin (16, 17, 45) . All of the agammaglobulinemic cell lines were examined during the 1st mo after they were established and at least once again after 6-12 mo of culture. We saw no alterations in the phenotype of the cell lines. In particular, the IgDbearing cell lines that did not produce immunoglobulin had this phenotype from the time of being established. This phenotype was stable.
The IgD-bearing LCL we studied were derived from surface IgD-and IgM-bearing B lymphocytes from patients with agammaglobulinemia.
The discordance of expression of surface and intracellular immunoglobulin in these cell lines reiterates previous studies which showed the independent expression of these two properties (46, 47) . The establishment of LCL that do not secrete immunoglobulin serves to dissociate the property of "immortalization" associated with EBV infection from the property of differentiation. The surface IgD-bearing LCL derived from patients with agammaglobulinemia present new opportunities for the study of B-lymphocyte development and differentiation. Unlike B lymphocytes from the patients' peripheral blood, they are available in unlimited quantities. Finally, detailed analysis of the properties of these cell lines may show alterations from the normal state which will confirm or deny hypothesized functions of B-lymphocyte properties.
